Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study

• Conditions: Ovarian Cancer

• Registration Number: NCT02719041
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-03
• Study First Submitted: 2016-03-13
• Study First Submitted QC: 2016-03-20
• Last Update Submitted: 2016-03-20
• Study First Posted: 2016-03-25
• Last Update Posted: 2016-03-25
• Study Start: 2016-04
• Primary Completion: 2018-04
• Study Completion: 2018-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• women who underwent surgery for ovarian cancer

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Responsive to IGF1R therapy	One year	Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.

Trial Locations

Locations (1)

Hillel Yaffe Medical Center; 🇮🇱 Hadera, Israel